Depressive disorders are highly prevalent and are associated with a substantial loss of quality of life for patients and their relatives, with increased levels of morbidity and mortality and with enormous economic costs. Although effective pharmacologic and psychological treatments are available, the effects are modest, relapse rates are high, and many patients do not respond to treatments at all. Current treatments can reduce only an estimated one-third of the disease burden of depression at the population level and only under optimal conditions, assuming that all people with major depression receive an evidence-based treatment.1 Depressive disorders can therefore be seen as one of the major public health challenges of the coming decades.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Cuijpers P, Reynolds CF. Increasing the Impact of Prevention of Depression—New Opportunities. JAMA Psychiatry. 2022;79(1):11–12. doi:10.1001/jamapsychiatry.2021.3153
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.